• Vaccine Name: MERS-CoV-S rNTD vaccine
• Target Pathogen: MERS-CoV
• Target Disease: Middle East Respiratory Syndrome (MERS)
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: Recombinant N-terminal domain (amino acids 18 - 353) of S1 subunit of S protein. (Chen et al., 2017)
• S from MERS-CoV gene engineering:
  • Type: Recombinant protein preparation
  • Description: baculovirus-insect cell sf9-derived recombinant MERS-CoV was used to express rNTD (Chen et al., 2017)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the N-terminal domain (NTD) of the MERS-CoV S1 subunit (Chen et al., 2017)

Mouse Response

• Host Strain: Balb/c (Chen et al., 2017)
• Host age: 6-8 weeks (Chen et al., 2017)
• Host gender: Female (Chen et al., 2017)
• Vaccination Protocol: 35 μg MERS-CoV rS combined with 150 μL Freund’s complete adjuvant (Sigma, St Louis, CA, USA) via subcutaneous immunization and boosted twice at 2-week intervals beginning three weeks after the initial immunization (Chen et al., 2017)
• Immune Response: anti-S protein IgG response and neutralizing activity (Chen et al., 2017)